Blackstone agreed to invest $2bn in Alnylam Pharmaceuticals, a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics. "Blackstone is uniquely positioned to provide customized, one-stop-shop financing solutions at scale while establishing development collaborations with the world’s leading biotech companies. Alnylam’s RNAi technology represents one of the most promising and rapidly advancing frontiers in biology and drug development today, and aligns perfectly with our investment strategy. Our collaboration with Alnylam provides non-dilutive access to capital to advance important new medicines in development across several disease indications including heart disease, the leading cause of death in the US and globally," Nicholas Galakatos, Blackstone Life Sciences Global Head. On Aug 17, Blackstone and Alnylam announced companies closed $150m R&D financing.